Animal data show VEGF blocker inhibits post-traumatic OA

Barranco, Caroline

doi:10.1038/nrrheum.2014.173

Cited by 17 publications

(9 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nagai et al (2014) showed that early treatment with bevacizumab in an OA rabbit model showed reduction of articular cartilage degeneration, osteophyte formation, synovitis, and pain. (52,134) Results were better overall with lower dose IA injection of bevacizumab in the knee compared with higher dose IV treatment. Compared with control, bevacizumab treatment resulted in: (i) increased expression of collagen type II, aggrecan, and chondromodulin-1 (Chm-1) at the chondrocytes; (ii) decreased Runx2 expression at the subchondral bone; and Chondrocyte-mediated pathways of cartilage degeneration include VEGF-mediated chondrocyte upregulation of MMP-1, MMP-3, MMP-9, MMP-13, and ADAMTS-5.…”

Section: Pharmacologic Inhibition Of Vegf Signaling Pathways In Cartimentioning

confidence: 99%

See 1 more Smart Citation

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Hamilton

Nagao

Levine

et al. 2016

Journal of Bone and Mineral Research

213

188

View full text Add to dashboard Cite

Increased vascular endothelial growth factor (VEGF) levels are associated with OA progression. Indeed, VEGF appears to be involved in OA specific pathologies including cartilage degeneration, osteophyte formation, subchondral bone cysts and sclerosis, synovitis, and pain. Moreover, a wide range of studies suggests that inhibition of VEGF signaling reduces OA progression. This review highlights both the potential significance of VEGF in OA pathology and pain as well as potential benefits of inhibition of VEGF and its receptors as an OA treatment. With the emergence of the clinical use of anti-VEGF therapy outside of OA, both as high dose systemic treatments and low dose local treatments, these particular therapies are now more widely understood. Currently, there is no established disease-modifying drug available for patients with OA, which warrants continued study of the inhibition of VEGF in OA, as standalone or adjuvant therapy.

show abstract

Section: Pharmacologic Inhibition Of Vegf Signaling Pathways In Cartimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Hamilton

Nagao

Levine

et al. 2016

Journal of Bone and Mineral Research

213

188

View full text Add to dashboard Cite

show abstract

“…The significance of VEGF in the genesis of osteoarthritis is underscored by the observation that the inhibition of VEGF reduces the progression of osteoarthritis [57]. Thus, there are also structural and functional similarities between the second phase of fracture healing and osteoarthritis.…”

Section: The Second Phasementioning

confidence: 99%

Hypothesis on the Pathogenesis of Osteoarthritis

Neumann¹

2015

MOJOR

View full text Add to dashboard Cite

Osteoarthritic joint changes represent a common phenomenon that, given its progression, is difficult to treat. Accordingly, knowledge about the pathogenesis of osteoarthritis is important. This article compares the mechanism of secondary bone healing with that of osteoarthritis, and can show clear parallels based on numerous study findings. This leads to the hypothesis that osteoarthritis corresponds to a mechanism of bone healing in the wrong place.

show abstract

“…Another study by Lee and colleagues suggested that serum and synovial fluid VEGF levels were significantly greater in the RA patients than in the OA patients or healthy subjects [ 29 ]. Overall, these reports along with additional studies have described the importance and therapeutic benefit of VEGF/VEGFR-2 blockers and VEGF antagonists by ameliorating the symptoms of RA and OA [ 30 , 31 , 32 , 33 , 34 ]. Thalidomide (Apremilast, Celgene, Summit, NJ, United States) and paclitaxel (under the commercial name Paxceed™ Angiotech Pharmaceuticals Inc., Vancouver, BC, Canada) have already been tested in clinical trials for arthritic conditions.…”

Section: Role Of Vascular Endothelial Growth Factors Beyond Angiogmentioning

confidence: 99%

Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis

et al. 2017

View full text Add to dashboard Cite

Angiogenesis, the formation of new blood vessels from pre-existing ones is a biological process that ensures an adequate blood flow is maintained to provide the cells with a sufficient supply of nutrients and oxygen within the body. Numerous soluble growth factors and inhibitors, cytokines, proteases as well as extracellular matrix proteins and adhesion molecules stringently regulate the multi-factorial process of angiogenesis. The properties and interactions of key angiogenic molecules such as vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and angiopoietins have been investigated in great detail with respect to their molecular impact on angiogenesis. Since the discovery of angiogenic growth factors, much research has been focused on their biological actions and their potential use as therapeutic targets for angiogenic or anti-angiogenic strategies in a context-dependent manner depending on the pathologies. It is generally accepted that these factors play an indispensable role in angiogenesis. However, it is becoming increasingly evident that this is not their only role and it is likely that the angiogenic factors have important functions in a wider range of biological and pathological processes. The additional roles played by these molecules in numerous pathologies and biological processes beyond angiogenesis are discussed in this review.

show abstract

Animal data show VEGF blocker inhibits post-traumatic OA

Cited by 17 publications

References 1 publication

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Hypothesis on the Pathogenesis of Osteoarthritis

Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis

Contact Info

Product

Resources

About